Baseline characteristics and treatment response predictive of nAMD outcomes with ranibizumab therapy in treatment-naive patients: the RACER subgroup analysis

被引：0
|
作者：
Ching-Yao Tsai
Chien-Liang Wu
Cheng-Kuo Cheng
Yun-Dun Shen
Wen-Chuan Wu
Pei-Chang Wu
Arslan Tsai
Jiann-Torng Chen
机构：
[1] Taipei City Hospital,Institute of Public Health
[2] National Yang Ming Chiao Tung University,Department of Business Administration
[3] Fu Jen Catholic University,undefined
[4] Municipal Wan Fang Hospital,undefined
[5] Shin Kong Wu Ho-Su Memorial Hospital,undefined
[6] Taipei Medical University-Shung Ho Hospital,undefined
[7] Kang-Ning General Hospital,undefined
[8] Kaohsiung Medical University Chung-Ho Memorial Hospital,undefined
[9] Park One International Hospital,undefined
[10] Kaohsiung Chang Gung Memorial Hospital,undefined
[11] Clinical Development and Medical Affairs,undefined
[12] Novartis Taiwan,undefined
[13] Tri-Service General Hospital,undefined
[14] National Defense Medical Center,undefined
来源：
BMC Ophthalmology | / 23卷
关键词：
Anti-VEGF; BCVA; Clinical practice; CRT; nAMD; RACER; Ranibizumab; Real-world; Taiwan; Treatment switch; Treatment response;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Baseline characteristics and treatment response predictive of nAMD outcomes with ranibizumab therapy in treatment-naive patients: the RACER subgroup analysis
    Tsai, Ching-Yao
    Wu, Chien-Liang
    Cheng, Cheng-Kuo
    Shen, Yun-Dun
    Wu, Wen-Chuan
    Wu, Pei-Chang
    Tsai, Arslan
    Chen, Jiann-Torng
    [J]. BMC OPHTHALMOLOGY, 2023, 23 (01)
  • [2] Evolution over 4 years of enrollment of baseline characteristics of treatment-naive nAMD patients in the LUMINOUS study
    Souied, Eric H.
    Macfadden, Wayne
    Parikh, Soumil
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2018, 59 (09)
  • [3] The Effect of Systemic Parameters and Baseline Characteristics in Short-Term Response Analysis with Intravitreal Ranibizumab in Treatment-Naive Patients with Neovascular Age-Related Macular Degeneration
    Garcia-Quintanilla, Laura
    Almuina-Varela, Pablo
    Rodriguez-Cid, Maria Jose
    Gil-Martinez, Maria
    Abraldes, Maximino J.
    Gomez-Ulla, Francisco
    Gonzalez-Barcia, Miguel
    Mondelo-Garcia, Cristina
    Estany-Gestal, Ana
    Otero-Espinar, Francisco J.
    Fernandez-Rodriguez, Maribel
    Fernandez-Ferreiro, Anxo
    [J]. PHARMACEUTICS, 2024, 16 (01)
  • [4] OUTCOMES AT 1 YEAR WITH RANIBIZUMAB IN TREATMENT-NAIVE PATIENTS WITH NEOVASCULAR AGERELATED MACULAR DEGENERATION (NAMD): REAL-WORLD RESULTS FROM THE LUMINOUS STUDY
    Mitchell, Paul
    Macfadden, Wayne
    Lacey, Sue
    [J]. CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2016, 44 : 30 - 30
  • [5] Time to recurrence in neovascular age-related macular degeneration after ranibizumab treatment: baseline characteristics of treatment-naive patients enrolled in the ORACLE study
    Devin, Francois
    Fourmaux, Eric
    Quentel, Gabriel
    Uzzan, Joel
    Quaranta El-Maftouhi, Maddalena
    Francais-Maury, Catherine
    Roquet, Wilfried
    Castelnovo, Laurent
    Razavi, Sam
    Finzi, Laetitia
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2016, 57 (12)
  • [6] Is disease activity prior to fingolimod initiation in treatment-naive patients predictive of response?
    Pantazou, V.
    Du Pasquier, R.
    Le Goff, G.
    Pot, C.
    Theaudin, M.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 166 - 166
  • [7] Subgroup analysis of the non-interventional study VIVALDI: Agomelatine in treatment-naive patients, in combination therapy and aft er treatment switch
    Laux, Gerd
    Huttner, Nadja A.
    [J]. INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE, 2014, 18 (02) : 86 - 96
  • [8] Characteristics of Treated and Treatment-Naive Patients with MS: A Retrospective Claims Analysis
    Mehta, I.
    Krzywy, H.
    Everage, N.
    Eaton, S.
    White, K.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (1_SUPPL) : 104 - 105
  • [9] Contribution of Obinutuzumab to Acalabrutinib Therapy in Patients with Treatment-Naive CLL: Analysis of Survival Outcomes By Genomic Features
    Sharman, J. P.
    Egyed, M.
    Jurczak, W.
    [J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (02) : 11 - 12
  • [10] A biological therapy for systemically treatment-naive patients with psoriasis
    不详
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2021, 35 (03) : 565 - 565
12345